Physician profile
Robert L Donley
NPI 1669479481
$5,297.43
in general payments reported to CMS, 2019-2025
16 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,612 · 2020: $43.38 · 2021: $206 · 2022: $121 · 2023: $185 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $315.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,330.81 | 2019-2025 | |
| Minerva Surgical, INC | $287.46 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $216.90 | 2021-2023 | Farxiga |
| Abbvie INC. | $91.58 | 2019-2021 | |
| Pfizer INC. | $80.03 | 2021-2023 | |
| Hologic Sales and Service, LLC | $42.39 | 2019 | |
| Ethicon US, LLC | $40.02 | 2021-2022 | |
| Coopersurgical, INC. | $38.02 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.96 | 2019-2023 | |
| Cumberland Pharmaceuticals, INC. | $28.30 | 2022-2023 | Caldolor |
| Organon LLC | $22.08 | 2022 | |
| Astellas Pharma US INC | $20.21 | 2023 | Veozah |
| Sumitomo Pharma America, INC. | $18.56 | 2023 | Myfembree |
| Pacira Pharmaceuticals Incorporated | $18.36 | 2022 | |
| Merck Sharp & Dohme LLC | $15.99 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $12.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Donley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.